image
Healthcare - Biotechnology - NASDAQ - US
$ 2.4
0.84 %
$ 332 M
Market Cap
-6.0
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CMPX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.4 USD, Compass Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CMPX stock under the base case scenario is HIDDEN Compared to the current market price of 2.4 USD, Compass Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on Jun, 21, 2025.

The intrinsic value of one CMPX stock under the best case scenario is HIDDEN Compared to the current market price of 2.4 USD, Compass Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CMPX

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Jan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 Jun
FINANCIALS
0 REVENUE
0.00%
-50.4 M OPERATING INCOME
-20.91%
-42.5 M NET INCOME
-8.33%
-40.6 M OPERATING CASH FLOW
-19.03%
27 M INVESTING CASH FLOW
117.83%
2.94 M FINANCING CASH FLOW
-96.13%
0 REVENUE
0.00%
-12.2 M OPERATING INCOME
18.65%
-10.5 M NET INCOME
19.86%
-11.1 M OPERATING CASH FLOW
-2.76%
29 M INVESTING CASH FLOW
347.60%
-2 K FINANCING CASH FLOW
-200.00%
Balance Sheet Compass Therapeutics, Inc.
image
Current Assets 154 M
Cash & Short-Term Investments 152 M
Receivables 0
Other Current Assets 1.42 M
Non-Current Assets 2.99 M
Long-Term Investments 0
PP&E 2.67 M
Other Non-Current Assets 320 K
97.19 %Total Assets$156.9m
Current Liabilities 7.8 M
Accounts Payable 4.09 M
Short-Term Debt 1.2 M
Other Current Liabilities 2.51 M
Non-Current Liabilities 536 K
Long-Term Debt 536 K
Other Non-Current Liabilities 0
49.06 %14.36 %30.15 %6.43 %Total Liabilities$8.3m
EFFICIENCY
Earnings Waterfall Compass Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 1.89 M
Gross Profit -1.89 M
Operating Expenses 48.5 M
Operating Income -50.4 M
Other Expenses -7.87 M
Net Income -42.5 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)0(2m)(2m)(48m)(50m)8m(42m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-28.61% ROE
-28.61%
-27.09% ROA
-27.09%
-33.51% ROIC
-33.51%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Compass Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)Jul '19Jul '1920202020Jul '20Jul '2020212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024
Net Income -42.5 M
Depreciation & Amortization 1.89 M
Capital Expenditures -30 K
Stock-Based Compensation 6.12 M
Change in Working Capital -2.91 M
Others 2.35 M
Free Cash Flow -40.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Compass Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CMPX of $5.5 , with forecasts ranging from a low of $5 to a high of $6 .
CMPX Lowest Price Target Wall Street Target
5 USD 108.33%
CMPX Average Price Target Wall Street Target
5.5 USD 129.17%
CMPX Highest Price Target Wall Street Target
6 USD 150.00%
Price
Max Price Target
Min Price Target
Average Price Target
66554433221100Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25May '25May '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26May '26May '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Compass Therapeutics, Inc.
image
Sold
0-3 MONTHS
11.4 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
80.3 K USD 3
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Squarepoint Ops LLC Acquires New Holdings in Compass Therapeutics, Inc. (NASDAQ:CMPX) Squarepoint Ops LLC acquired a new stake in Compass Therapeutics, Inc. (NASDAQ:CMPX – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 24,072 shares of the company’s stock, valued at approximately $35,000. A number of other large investors have also recently added to or reduced their stakes in the business. Rhumbline Advisers grew its stake in Compass Therapeutics by 3.1% in the 4th quarter. Rhumbline Advisers now owns 129,116 shares of the company’s stock valued at $187,000 after acquiring an additional 3,822 shares during the last quarter. Invesco Ltd. grew its stake in Compass Therapeutics by 11.3% in the 4th quarter. Invesco Ltd. now owns 39,483 shares of the company’s stock valued at $57,000 after acquiring an additional 4,018 shares during the last quarter. Bank of New York Mellon Corp grew its stake in Compass Therapeutics by 2.6% in the 4th quarter. Bank of New York Mellon Corp now owns 237,975 shares of the company’s stock valued at $345,000 after acquiring an additional 6,041 shares during the last quarter. ProShare Advisors LLC grew its stake in Compass Therapeutics by 49.0% in the 4th quarter. ProShare Advisors LLC now owns 28,722 shares of the company’s stock valued at $42,000 after acquiring an additional 9,451 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in Compass Therapeutics by 31.8% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 46,942 shares of the company’s stock valued at $69,000 after acquiring an additional 11,326 shares during the last quarter. 68.43% of the stock is owned by institutional investors and hedge funds. Analyst Upgrades and Downgrades CMPX has been the topic of several analyst reports. Guggenheim decreased their price target on shares of Compass Therapeutics from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Friday, May 9th. Leerink Partners raised shares of Compass Therapeutics from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $4.00 to $6.00 in a research note on Wednesday, April 2nd. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Tuesday, April 1st. D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price target on shares of Compass Therapeutics in a research note on Monday, April 28th. Finally, Leerink Partnrs raised shares of Compass Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, April 1st. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $13.13. View Our Latest Stock Analysis on CMPX Insiders Place Their Bets In related news, insider Jonathan Anderman acquired 20,000 shares of Compass Therapeutics stock in a transaction that occurred on Monday, April 7th. The stock was acquired at an average price of $1.54 per share, with a total value of $30,800.00. Following the completion of the acquisition, the insider now directly owns 21,000 shares of the company’s stock, valued at $32,340. This trade represents a 2,000.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Carl L. Gordon sold 3,571,428 shares of the business’s stock in a transaction dated Wednesday, April 9th. The stock was sold at an average price of $1.59, for a total transaction of $5,678,570.52. The disclosure for this sale can be found here. 29.80% of the stock is currently owned by corporate insiders. Compass Therapeutics Stock Performance CMPX opened at $2.51 on Wednesday. The company’s 50 day simple moving average is $1.95 and its 200 day simple moving average is $2.17. Compass Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $4.08. The stock has a market capitalization of $347.09 million, a PE ratio of -6.78 and a beta of 1.41. Compass Therapeutics (NASDAQ:CMPX – Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.12) EPS for the quarter, meeting the consensus estimate of ($0.12). As a group, sell-side analysts expect that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current fiscal year. Compass Therapeutics Company Profile (Free Report) Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. https://www.defenseworld.net - 1 week ago
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference BOSTON, May 28, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in a fireside chat at the Jefferies Global Healthcare Conference taking place June 3-5, 2025. Fireside Chat Details Date: Thursday, June 5, 2025Time: 11:05 – 11:35 AM ETWebcast Link: https://wsw.com/webcast/jeff319/cmpx/1867328 Virtual/Replay availability: The fireside chat will be archived for 90 days on Compass' Events page. globenewswire.com - 3 weeks ago
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio. seekingalpha.com - 1 month ago
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. globenewswire.com - 1 month ago
Compass Therapeutics to Participate in Upcoming May Investor Events BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. globenewswire.com - 1 month ago
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models. globenewswire.com - 1 month ago
2 Penny stocks to buy in May 2025 Summary ⚈ Market conditions in May create opportunities for penny stock investors.⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects. finbold.com - 1 month ago
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center. globenewswire.com - 2 months ago
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. globenewswire.com - 2 months ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review. globenewswire.com - 2 months ago
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC). globenewswire.com - 2 months ago
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025. globenewswire.com - 3 months ago
8. Profile Summary

Compass Therapeutics, Inc. CMPX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 332 M
Dividend Yield 0.00%
Description Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Contact 80 Guest Street, Boston, MA, 02135 https://www.compasstherapeutics.com
IPO Date April 5, 2021
Employees 35
Officers Mr. Neil L. Lerner CPA Senior Vice President & Chief Accounting Officer Dr. Thomas J. Schuetz M.D., Ph.D. Chief Executive Officer & Vice Chairman Ms. Karin Herrera B.A. Senior Vice President & Head of Clinical Operations Anna Gifford Communications Manager Dr. James Kranz Ph.D. Vice President and Head of Chemistry Manufacturing & Controls Ms. Vered Bisker-Leib MBA, Ph.D. Advisor Mr. Barry Shin J.D., M.B.A. Chief Financial Officer Dr. Minori Rosales M.D., Ph.D. Senior Vice President & Head of Clinical Development Mr. Jonathan E. Anderman J.D. Senior Vice President, General Counsel & Corporate Secretary